Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Cyclazodone

This article is a stubmissing:
Subjective Effects
Pharmacology
Tolerance
History & Culture
Cyclazodone molecule structureCyclazodone molecule structure
N-Cyclopropylpemoline
Cyclopropylpemoline, Cyclazadone
Psychoactive Class
Chemical Class

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold5 mg
Light5-15 mg
Moderate15-25 mg
Strong25-60 mg
Heavy60+ mg

Duration

Onset20-45 minutes
Total5-7 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacology not written up yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholDXMDissociativesMDMAMXENBOMe compoundsStimulantsTramadol
Powered by TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Moderate

Heavy recreational stimulant use carries a serious addiction risk, but typical long-term therapeutic dosing is unlikely to produce addiction. The related compound pemoline appears to have lower dependence risk than more typical dopaminergic stimulants, although caution remains appropriate for monoamine releasing agents.

Toxicity

Lethal Dosage

The exact toxic dosage is unknown due to cyclazodone's very limited history of human usage.

Hepatic

Heavy or sustained use may cause liver damage. Because pemoline, a structurally related drug, was withdrawn after liver injury was identified in children, cyclazodone may also have hepatotoxic properties.

Cardiovascular

The structurally related compound 4-methylaminorex is associated with pulmonary hypertension, though it induces far stronger stimulation than cyclazodone; mouse studies suggest cyclazodone exhibited less cardiotoxic effects than D-amphetamine.

Central Nervous System

At high doses, monoamine releasers may indirectly harm neurons by increasing oxidative burden, including reactive oxygen species and dopamine autoxidation; typical human doses have not been shown to cause direct neurotoxicity from releasing agents.

Psychosis Risk

Moderate

Based on pharmacological similarity to other stimulants, misuse of this compound can likely result in a state of psychosis marked by paranoia, hallucinations, or delusions. Approximately 5-15% of stimulant users who develop psychosis fail to recover completely. Sustained high-dose use combined with sleep deprivation makes stimulant psychosis more likely. Psychosis very rarely arises from therapeutic use.

History & Culture

History & Culture not written up yet

Legality

By Country

Controlled / restricted1
Germany flagGermanyRestricted
Not scheduled2
United States flagUnited StatesNot scheduled
Switzerland flagSwitzerlandNot scheduled

References

Source Pages

  1. Bluelight: Cyclazodone Discussion
  2. Bluelight: Cyclazodone Megathread
  3. Bluelight: Cyclazodone Safety Discussion
  4. Erowid: Cyclazodone Experience Report
  5. Erowid: Cyclazodone Experience Report
  6. Isomer Design (TiHKAL/PiHKAL)
  7. PsychonautWiki
  8. Wikipedia

Citations

  1. BGBl. 2025 II Nr. 312 - Bekanntmachung der Neufassung der Anlage I zu dem Internationalen Übereinkommen gegen Doping im Sport (2026 Prohibited List). recht.bund.de (n.d.). https://www.recht.bund.de/bgbl/2/2025/312/regelungstext.pdf?__blob=publicationFile&v=31
  2. PubChem PUG View - Cyclazodone (CID 135438121). pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/compound/135438121/JSON1
  3. § 2 AntiDopG - Unerlaubter Umgang mit Dopingmitteln, unerlaubte Anwendung von Dopingmethoden. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/antidopg/__2.html1
  4. § 3 AntiDopG - Selbstdoping. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/antidopg/__3.html1
  5. Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (BetmVV-EDI), Stand am 13. März 2026. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/html/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-html-3.html1
  6. Swissmedic — Listen und Verzeichnisse: Betäubungsmittel und Vorläuferstoffe. swissmedic.ch (n.d.). https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html1
  7. PubChem PUG REST — Cyclazodone identity record (CID 135438121). pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/cyclazodone/property/IUPACName,Title,CanonicalSMILES,IsomericSMILES,MolecularFormula/JSON1
  8. PubChem PUG REST — Cyclazodone synonyms (CID 135438121). pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/135438121/synonyms/JSON1
  9. Title 21—Food and Drugs, Chapter II, Part 1308—Schedules of Controlled Substances. govinfo.gov (n.d.). https://www.govinfo.gov/content/pkg/CFR-2025-title21-vol9/xml/CFR-2025-title21-vol9-part1308.xml1
  10. 21 CFR § 1308.14—Schedule IV. govinfo.gov (n.d.). https://www.govinfo.gov/link/cfr/21/1308?link-type=pdf&sectionnum=14&year=mostrecent1

Further Reading

  1. ChemSpider: Cyclazodone Chemical Structure
  2. Guidicelli Patent: US3609159A
  3. Miller (2011): TAAR1 and Monoamine Transporters
  4. NDEWS: Cyclazodone Web Monitoring Alert
  5. PubChem: Cyclazodone
  6. Toxicity Case Report: N-Methyl-Cyclazodone

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Cyclazodone article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.